Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals
Key points are not available for this paper at this time.
Abstract
These findings support the efficacy and safety profile of durvalumab in real-world settings.
问 AI
Like
Bookmark
Share
View Full Paper
问 AI
Like
Bookmark
Share
View Full Paper
Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals | Synapse